4-Hydroxytamoxifen (Afimoxifene) vs Arimistane

Hormone

Hormone

Research Only

Research Only

Afimoxifene is a competitive antagonist/partial agonist at estrogen receptors alpha and beta, exhibiting tissue-selective activity characteristic of SERMs. Receptor-binding studies on estrogen receptors isolated from human breast carcinoma found 4-hydroxytamoxifen binds ER with affinity equal to estradiol and 25–50× higher than tamoxifen itself, which is why it is considered tamoxifen's principal active metabolite despite low circulating abundance (2–18% of parent drug). Unlike tamoxifen and endoxifen, whose formation depends on hepatic CYP2D6/CYP3A4 activity, 4-hydroxytamoxifen is already the pharmacologically active hydroxylated species, which is the rationale for delivering it directly (e.g., as a topical gel) to bypass variable CYP2D6-dependent bioactivation of oral tamoxifen.

Arimistane is a C19 steroid bearing 7,17-diketone groups on an androsta-3,5-diene core, marketed as a mechanism-based ("suicide") irreversible aromatase inhibitor. Direct enzyme-kinetics data (Ki, kinact) specifically for arimistane were not found in primary literature; the closest sourced data are for near-neighbor steroids: androst-5-ene-7,17-dione (differing only in lacking the 3,4-double bond) acts as a time-dependent, NADPH-dependent suicide substrate of human placental aromatase in vitro (Ki ~0.14–35 µM, kinact ~0.036–0.19/min), and a series of androsta-3,5-dien-7-ones/androst-5-en-7-ones competitively inhibited aromatase with Ki 0.058–45 µM (17-oxo forms more potent than 17-beta-ols). These class data support the aromatase-inhibitor assignment but do not confirm kinetics for arimistane itself.